drugset / Trial / NCT02935634

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

NCT02935634

Phase 2 Completed 190 enrolled Bristol-Myers Squibb Clovis Oncology, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.

Timeline

Start
2016-11-29
Primary completion
2022-05-11
Completion
2022-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody
Subject LINRODOSTAT Small molecule
Subject Nivolumab Monoclonal antibody
Subject Relatlimab Monoclonal antibody
Subject Rucaparib Small molecule

Indications